Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice

https://doi.org/10.1016/j.intimp.2012.03.002Get rights and content

Abstract

Suppression of interleukin (IL)-6 production has beneficial effects against various inflammatory diseases. Through a rapid screening system, we found that nitazoxanide, or 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, which is a well-known antiparasitic agent, suppressed lipopolysaccharide (LPS)-induced production of IL-6 from RAW 264.7 cells and mouse peritoneal macrophages, with 50% inhibitory concentrations (IC50s) of 1.54 mM and 0.17 mM, respectively. Nitazoxanide also inhibited the LPS-induced expression of IL-6 mRNA in RAW 264.7 cells. To investigate the effects of nitazoxanide in vivo, we orally administered nitazoxanide at a dose of 100 mg/kg to mice 2 h before a 1-mL intraperitoneal injection of 4% thioglycollate (TG). Six hours after TG injection, plasma IL-6 levels were markedly lower (by 90%) than the levels in vehicle-treated mice. These data suggest that nitazoxanide could be a promising lead compound for agents against various diseases associated with overproduction of IL-6.

Highlights

► Nitazoxanide suppresses the production of IL-6 from LPS-stimulated macrophages. ► Nitazoxanide inhibits the LPS-induced expression of IL-6 mRNA in RAW 264.7 cells. ► Orally administered nitazoxanide suppresses the increase in IL-6 levels in the blood of thioglycollate-injected mice. ► Nitazoxanide could be a promising lead compound for agents against various diseases associated with overproduction of IL-6.

Introduction

Interleukin (IL)-6 is a multifunctional cytokine produced by a wide variety of cells, including fibroblasts, epithelial cells, macrophages, dendritic cells, mesangial cells, T cells, and B cells. IL-6 stimulates proliferation of hematopoietic progenitors, terminal differentiation of B cells into plasma cells, and activation and differentiation of T cells [1]. IL-6, together with IL-1β and tumor necrosis factor (TNF)-α, is also a proinflammatory cytokine that activates the hypothalamic-pituitary–adrenal axis and induces the hepatic acute phase response [2]. The biological activities of IL-6 integrate the innate and adaptive immune systems; therefore, IL-6 is involved in the host's defense response against pathogens.

Although IL-6 is pivotal in the development of immune responses, irregular production of IL-6 has been implicated in the development of various diseases. Abnormally high levels of IL-6 are detected in the serum of mice with inflammatory diseases, including multiple sclerosis [3], rheumatic arthritis [4], and host-versus-graft disease [5]. Constitutive expression of IL-6 in the liver of IL-6 transgenic mice causes glomerulonephritis [6]. Moreover, overproduction of IL-6 is strongly associated with the progression of neoplastic diseases such as Kaposi's sarcoma, multiple myeloma, renal carcinoma, plasmacytoma, and prostate cancer [7]. Therefore, inhibition of IL-6 production may be therapeutic in diseases characterized by IL-6 overproduction.

In response to lipopolysaccharide (LPS), the murine macrophage cell line RAW 264.7 readily secretes various pro-inflammatory mediators, including IL-6, IL-1β, TNF-α, nitric oxide, and prostaglandin E2 (PGE2). In this study, we used this cell line to find a potent inhibitor of IL-6 production. The levels of IL-6 in the culture supernatant of LPS-stimulated RAW 264.7 cells were determined by enzyme-linked immunosorbent assay (ELISA) in the presence of a compound. From our in-house stock compounds, we found that nitazoxanide, or 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide (Fig. 1), inhibited the production of IL-6 in a concentration-dependent manner.

Nitazoxanide is a thiazolide compound that has long been used as an antiparasitic agent against protozoa, nematodes, and trematodes [8]. Nitazoxanide also has antimicrobial activity against some bacteria [9], [10] and viruses [11]. However, anti-inflammatory activities have never been reported for nitazoxanide. In this study, we report the first demonstration of the inhibitory activity of nitazoxanide on the production of IL-6 in vitro and in vivo.

Section snippets

Reagents

Nitazoxanide, LPS (Escherichia coli serotype O55; B5), Neutral Red, and thioglycollate broth (TG) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) and Dulbecco's modified Eagle's medium (DMEM) were obtained from Gibco (Grand Island, NY, USA). Nitazoxanide was dissolved as a 200 mM stock solution in dimethyl sulfoxide (DMSO). The final concentration of DMSO in culture media was less than 0.5%. For oral administration, nitazoxanide was dissolved in 1% DMSO in

The inhibitory activity of nitazoxanide on IL-6 production from RAW 264.7 cells stimulated with LPS

In the search for a compound with inhibitory activity against IL-6 production, we utilized a rapid screening system where IL-6 production from RAW 264.7 cells stimulated with LPS in the presence of each compound at a single concentration was determined by ELISA. From an in-house stock of 80 compounds, we found that nitazoxanide had such inhibitory activity. RAW 264.7 cells stimulated with LPS at a concentration of 1 μg/mL for 18 h produced an average of 1763.5 pg/mL of IL-6, which was

Discussion

Overproduction of IL-6 leads to various diseases, including inflammation, autoimmune disease, and even cancer. With a goal of developing a therapeutic agent for diseases associated with deregulated IL-6 production, we screened in-house stocks using a rapid screening system with LPS-stimulated RAW 264.7 cells. We found that nitazoxanide, a well-known antiparasitic agent, has inhibitory activity against IL-6 production in RAW 264.7 cells and peritoneal macrophages stimulated with LPS.

References (29)

  • A.C. White

    Nitazoxanide: an important advance in anti-parasitic therapy

    Am J Trop Med Hyg

    (2003)
  • C.S. McVay et al.

    In vitro and in vivo activities of nitazoxanide against Clostridium difficile

    Antimicrob Agents Chemother

    (2000)
  • F. Megraud et al.

    Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole

    Antimicrob Agents Chemother

    (1998)
  • L.V. Ashton et al.

    In vitro susceptibility of canine influenza A (H3N8) virus to nitazoxanide and tizoxanide

    Vet Med Int

    (2010)
  • Cited by (52)

    • Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research

      2023, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
    • A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19

      2022, eClinicalMedicine
      Citation Excerpt :

      In the 25 years since nitazoxanide was first introduced, approximately 500 million people have been treated worldwide, and the drug has demonstrated a favorable safety record in both adults and children. Nitazoxanide has been previously shown to be active in vitro against a broad range of viruses including MERS and certain animal coronaviruses6–8 and suppress secretion of cytokines associated with the inflammatory response to respiratory infection.9,10 Recently, nitazoxanide was identified as a candidate drug for SARS-CoV-2 infection based on high throughput screening and in vitro virus culture.11–15

    • Interferon-inducer antivirals: Potential candidates to combat COVID-19

      2021, International Immunopharmacology
      Citation Excerpt :

      Given the presence of mTOR catalytic subunit in both mTORC1 and mTORC2, it could possibly block the kinase activity of mTOR indirectly, and might probably affect the upstream mTORC1 regulatory pathway [103]. One study showed that it exerted inhibitory activity against IL-6 production from murine macrophages both in vitro and in vivo [104]. NTZ also enhanced the IRF3-induced IFNβ reporter activity in a dose-dependent way, and in the RIG-I overexpressing cells triggered with 1AB.

    View all citing articles on Scopus
    View full text